WO2021130453A1 - Formulation d'un dendrimère anti-inflammatoire pour le traitement de psoriasis - Google Patents
Formulation d'un dendrimère anti-inflammatoire pour le traitement de psoriasis Download PDFInfo
- Publication number
- WO2021130453A1 WO2021130453A1 PCT/FR2020/052608 FR2020052608W WO2021130453A1 WO 2021130453 A1 WO2021130453 A1 WO 2021130453A1 FR 2020052608 W FR2020052608 W FR 2020052608W WO 2021130453 A1 WO2021130453 A1 WO 2021130453A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dendrimer
- skin
- vesicle
- nmr
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
Definitions
- the present invention relates to vesicles of catanionic surfactants derived from sugar comprising anti-inflammatory dendrimers and their use as a medicament, more particularly in the treatment of psoriasis.
- Psoriasis is a chronic inflammatory disease of the skin which is the consequence of an accelerated renewal of the epidermis maintained by the inflammation and which manifests itself by the appearance of red plaques covered with white films which stand out from the skin. the skin (dander). This disease which affects more than 125 million people worldwide and has a strong impact on the quality of life of those affected. No treatment can cure psoriasis today and the causes of this disease are multiple and still poorly understood.
- Treatments making it possible to alleviate the symptoms have however been developed such as the topical application of corticosteroids or vitamin D. These treatments make it possible to relieve the mild symptoms of psoriasis but are not very effective for the treatment of the most severe forms. more severe. The more severe forms are treated by oral administration of immunosuppressants such as cyclosporine, but these cause significant side effects. Monoclonal antibodies and soluble receptors targeting pro-inflammatory mediators such as TNF, IL-12, IL-23 and IL-17 have been proposed. These biological drugs have a high cost and see their effectiveness decrease over time. They are also contraindicated in the case of certain co-morbidities associated with psoriasis. [0004] There therefore remains a need to develop new treatments for the treatment of psoriasis for topical application, thus limiting the side effects.
- Dendrimers are macromolecules made up of monomers combined together to form a multi-branched three-dimensional architecture with a defined structure.
- the dendrimers have a perfectly defined size and structure thanks to their iterative synthesis. Their multivalence makes them very attractive nano-objects for many applications, particularly in biology and medicine.
- phosphorus-containing dendrimers with an Azabisphosphonate surface are capable of activating monocytes and inducing an anti-inflammatory response (WO2010 / 013086, Portevin D. et al. J Transi Med. 2009; 7 : 82). More specifically, the anti-inflammatory properties have been validated in animal models of rheumatoid arthritis in which monocytes are known to play a primary role in inflammation and osteoclastogenesis (Hayder M. et al. 2011; Sci Trans Med. 3 (81)). The anti-inflammatory effect of the ABP dendrimer has also been validated in models of uveitis (Fruchon et al. 2013.
- the inventors have formulated the aza-bisphosphonate dendrimers with catanionic surfactants derived from sugar.
- Catanionic surfactants sugar derivatives associate spontaneously in the form of vesicles and can encapsulate hydrophobic active ingredients in their membrane bilayer.
- hydrophilic ABP dendrimers exhibit a low level of encapsulation with surfactants derived from sugar and a transition temperature of the "solid-fluid" phase of the membrane bilayer of 37 ° C
- the inventors have discovered in such a way It is surprising that the complex formed as a result of the combination of the phosphonic acid form of the ABP dendrimer (ABP-OH) with a surfactant derived from sugar results in a decrease in the transition temperature of the complex to 33 ° C.
- this complex becomes fluid and is therefore able to diffuse more easily into the deep layers of the skin, also improving its anti-inflammatory action.
- the rate of encapsulation of these phosphonic acid forms is higher than that of hydrophilic ABP dendrimers and the complexes are stable at a pH close to that of the skin.
- the invention relates to a vesicle comprising:
- R 1 is chosen from H and a linear or branched, saturated or unsaturated, 1 to 20 membered hydrocarbon chain,
- R 2 is a linear or branched, saturated or unsaturated, 1 to 20 membered hydrocarbon chain
- R 3 and R 4 are independently of each other a linear hydrocarbon chain or branched, saturated or unsaturated, 1 to 19 membered; and - a dendrimer of formula (II):
- R is chosen from H and C1-C12-alkyl
- A is chosen from where X is chosen from S and O, and n is an integer between 3 and 8.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one vesicle according to the invention and a pharmaceutically acceptable excipient.
- the invention relates to a vesicle according to the invention or to a pharmaceutical composition according to the invention for its use in the treatment of psoriasis.
- the invention relates to a process for preparing a vesicle according to the invention.
- FIG. 1 represents a diagram illustrating the production of the bioactive formulation.
- Fig. 2 represents a diagram illustrating the production of the bioactive formulation.
- FIG. 2 shows the phase transition temperature for the TriCat 12 / ABP formulation.
- FIG. 3 shows the fluorescence quantification of the quantity of ABP-NIR dendrimer (ABP dendrimer in its fluorescent form), whether or not formulated with TriCat 12, which has penetrated into the skin of the pig's ear (Franz cells) after 24 hours at 40 ° C.
- FIG. 4 shows in a) the size distribution measured by DLS of the vesicles formed by the TriCat 12 / G1-A formulation (1 / 0.5), b) the scanning electron microscopy image of the vesicles formed by the TriCat formulation 12 / G 1 - A (1 / 0.5).
- FIG. 5 shows the phase transition temperature of the TriCat 12 / G1-A formulation.
- FIG. 6 shows the measurement of the mean hydrodynamic diameter and the DLS intensity of the TriCat 12 / G1-A formulation over two months at 4 ° C.
- Fig. 7 shows the measurement of the mean hydrodynamic diameter and the DLS intensity of the TriCat 12 / G1-A formulation over two months at 4 ° C.
- FIG. 7 shows the measurement of the mean hydrodynamic diameter and the DLS intensity of the TriCat 12 / G1-A formulation over two months at + 4 ° C and - 20 ° C.
- Fig. 8 shows the measurement of the mean hydrodynamic diameter and the DLS intensity of the TriCat 12 / G1-A formulation over two months at + 4 ° C and - 20 ° C.
- FIG. 8 shows the fluorescence quantification of the quantity of G1A-NIR dendrimer (G1A dendrimer in its fluorescent form), whether or not formulated with TriCat 12, which has penetrated into the skin of the pig's ear (Franz cells) after 24 hours at 35 ° C.
- Fig. 9 shows the fluorescence quantification of the quantity of G1A-NIR dendrimer (G1A dendrimer in its fluorescent form), whether or not formulated with TriCat 12, which has penetrated into the skin of the pig's ear (Franz cells) after 24 hours at 35 ° C.
- Fig. 9 shows the fluorescence quantification of the quantity of G1A-NIR dendrimer (G1A dendrimer in its fluorescent form), whether or not formulated with TriCat 12, which has penetrated into the skin of the pig's ear (Franz cells) after 24 hours at 35 ° C.
- Fig. 9 shows the fluorescence quantification of the quantity of G1A
- FIG. 9 shows the observation by confocal microscopy of the fluorescence (in white) of the unformulated G1-A-NIR dendrimer (left image) and formulated with T riCat 12 (right image) which has penetrated the skin of pig's ear (Franz cells) after 24 hours at 35 ° C.
- Fig. 10 shows the observation by confocal microscopy of the fluorescence (in white) of the unformulated G1-A-NIR dendrimer (left image) and formulated with T riCat 12 (right image) which has penetrated the skin of pig's ear (Franz cells) after 24 hours at 35 ° C.
- Fig. 10 shows the observation by confocal microscopy of the fluorescence (in white) of the unformulated G1-A-NIR dendrimer (left image) and formulated with T riCat 12 (right image) which has penetrated the skin of pig's ear (Franz cells) after 24 hours at 35
- FIG. 10 shows the observation by confocal microscopy of the fluorescence (in white) of the unformulated G1-A-NIR dendrimer (left image) and formulated with TriCat 12 (right image) which has penetrated human skin (cells de Franz) after 24 hours at 35 ° C.
- Fig. 11 shows the observation by confocal microscopy of the fluorescence (in white) of the unformulated G1-A-NIR dendrimer (left image) and formulated with TriCat 12 (right image) which has penetrated human skin (cells de Franz) after 24 hours at 35 ° C.
- Fig. 11 shows the observation by confocal microscopy of the fluorescence (in white) of the unformulated G1-A-NIR dendrimer (left image) and formulated with TriCat 12 (right image) which has penetrated human skin (cells de Franz) after 24 hours at 35 ° C.
- Fig. 11 shows the observation by confocal microscopy of the fluorescence (in white)
- FIG. 11 shows the analysis by flow cytometry of the morphology (size and granulosity) of the monocytes (on the graphs, each point is a cell).
- the top graph shows the unactivated control monocytes.
- the lower left graph shows the monocytes cultured in the presence of TriCat 12 vesicles alone (no activation).
- the lower right graph shows the monocytes cultured with the TriCat 12 vesicles loaded with the G1-A dendrimer. The activated monocytes are in the ellipse.
- FIG. 12 [0025] [Fig.12] shows the therapeutic efficacy of the G1-A dendrimer and the TriCat12 vesicles loaded with the G1-A dendrimer in the mouse model of psoriasis induced by Imiquimod (IMQ). Clinical scores (top graph) are given as a function of time expressed in days. Histological scores are given on the bottom graph. The "control" mice are the animals which have not been treated.
- FIG. 13 shows the antiproliferative effect of compound G1-A, as a function of the treatment time, on the N-TERT keratinocyte line (top graphs) and on primary human keratinocytes (bottom graphs).
- FIG. 14 shows in a) the size distribution measured by DLS of the vesicles formed by the TriCat 12 / G1-B formulation (1 / 0.5), b) scanning electron microscopy image of the vesicles formed by the TriCat 12 formulation / G1 -B (1 / 0.5).
- FIG. 15 shows the phase transition temperature of the TriCat 12 / G1-B formulation.
- Fig. 16 shows the measurement of the mean hydrodynamic diameter and the DLS intensity of the TriCat 12 / G1-B formulation over two months at 4 ° C.
- TriCat 12 / G1-B in xanthan gel (A) after 3 months storage at pH 4 at 25 ° C in water protected from light.
- FIG. 18 shows the evolution of light transmission, after 1 day in water at room temperature, through a sample of TriCat 12 / G1-B incorporated (bottom) or not (top) in a gel of xanthan (physical stabilization).
- Fig. 19 shows the evolution of light transmission, after 1 day in water at room temperature, through a sample of TriCat 12 / G1-B incorporated (bottom) or not (top) in a gel of xanthan (physical stabilization).
- FIG. 19 shows the fluorescence quantification of the amount of G1- B-NIR dendrimer (G1-B dendrimer in its fluorescent form), whether or not formulated with TriCat 12, which has penetrated into the skin of the pig's ear (Franz cells ) after 24 hours at 35 ° C.
- Fig. 20 shows the fluorescence quantification of the amount of G1- B-NIR dendrimer (G1-B dendrimer in its fluorescent form), whether or not formulated with TriCat 12, which has penetrated into the skin of the pig's ear (Franz cells ) after 24 hours at 35 ° C.
- Fig. 20 shows the fluorescence quantification of the amount of G1- B-NIR dendrimer (G1-B dendrimer in its fluorescent form), whether or not formulated with TriCat 12, which has penetrated into the skin of the pig's ear (Franz cells ) after 24 hours at 35 ° C.
- Fig. 20 shows the fluorescence
- FIG. 20 shows the observation by confocal microscopy of the fluorescence (in white) of the G1-B-NIR dendrimer (G1-B dendrimer in its fluorescent form) unformulated (A) and formulated with TriCat 12 (B) which has penetrated in pig ear skin (Franz cells) after 24 hours at 35 ° C.
- Fig. 21 shows the observation by confocal microscopy of the fluorescence (in white) of the G1-B-NIR dendrimer (G1-B dendrimer in its fluorescent form) unformulated (A) and formulated with TriCat 12 (B) which has penetrated in pig ear skin (Franz cells) after 24 hours at 35 ° C.
- Fig. 21 shows the observation by confocal microscopy of the fluorescence (in white) of the G1-B-NIR dendrimer (G1-B dendrimer in its fluorescent form) unformulated (A) and formulated with TriCat 12 (B) which has penetrate
- FIG. 21 shows the observation by confocal microscopy of the fluorescence (in white) of the G1-B-NIR dendrimer (G1-B dendrimer in its fluorescent form) unformulated (A) and formulated with TriCat 12 + xanthan 1% (B ) which has penetrated the skin of the pig's ear (Franz cells) after 24 hours at 35 ° C.
- FIG. 22 shows the analysis by flow cytometry of the morphology (size and granulosity) of the monocytes (on the graphs, each point is a cell).
- the top graph shows the unactivated control monocytes.
- the lower graph shows the monocytes cultured in the presence of TriCat 12 vesicles loaded with the G1-B dendrimer. The activated monocytes are in the ellipse.
- FIG. 23 shows the therapeutic efficacy of the G1-B dendrimer and the TriCat12 vesicles loaded with the G1-B dendrimer in the mouse model of imiquimod-induced psoriasis.
- Clinical scores (top graph) are given as a function of time expressed in days. Histological scores are given on the bottom graph. The "control" mice are the animals which have not been treated.
- Fig. 24 shows the therapeutic efficacy of the G1-B dendrimer and the TriCat12 vesicles loaded with the G1-B dendrimer in the mouse model of imiquimod-induced psoriasis.
- Clinical scores (top graph) are given as a function of time expressed in days. Histological scores are given on the bottom graph.
- the "control" mice are the animals which have not been treated.
- Fig. 24 shows the therapeutic efficacy of the G1-B dendrimer and the TriCat12 vesicles loaded with the G1-B dendrimer
- FIG. 24 shows the antiproliferative effect of compound G1-B, as a function of the treatment time, on the N-TERT keratinocyte line (top graphs) and on primary human keratinocytes (bottom graphs).
- FIG. 25 shows the size distribution measured by DLS of the vesicles formed by the TriCat 12 / G1-C formulation (1 / 0.5)
- FIG. 26 shows the phase transition temperature of the TriCat 12 / G1-C formulation Fig. 27
- FIG. 27 shows the measurement of the mean hydrodynamic diameter measured in DLS of the TriCat 12 / G1-C formulation over one month at 4 ° C.
- FIG. 28 shows the fluorescence quantification of the quantity of G1C-NIR dendrimer (G1C dendrimer in its fluorescent form) formulated with TriCat 12, which penetrated into the skin of pig's ear (Franz cells) after 24 hours at 35 ° vs.
- FIG. 29 shows the analysis by flow cytometry of the morphology (size and granulosity) of the monocytes (on the graphs, each point is a cell).
- the top graph shows the unactivated control monocytes.
- the lower graphs show the monocytes cultured with the G1-C dendrimer at 3 concentrations 0.2 ⁇ M, 2 pM and 20 pM.
- the activated monocytes are in the ellipse.
- Fig. 30 shows the analysis by flow cytometry of the morphology (size and granulosity) of the monocytes (on the graphs, each point is a cell).
- the top graph shows the unactivated control monocytes.
- the lower graphs show the monocytes cultured with the G1-C dendrimer at 3 concentrations 0.2 ⁇ M, 2 pM and 20 pM.
- the activated monocytes are in the ellipse.
- FIG. 30 shows the size distribution measured by DLS of the vesicles formed by the TriCat 8 / G1-B formulation (1 / 0.5)
- FIG. 31 shows the size distribution measured by DLS of the vesicles formed by the TriCat 16 / G1-B formulation (1 / 0.5)
- FIG. 32 shows the measurement of the mean hydrodynamic diameter measured in DLS of the TriCat 16 / G1-B formulation over 10 days at 4 ° C.
- the inventors have shown that the formulation of azabisphosphonate dendrimers in the phosphonic acid form with catanionic surfactants derived from sugar promotes the penetration of the dendrimer into the skin, thus improving its anti-inflammatory effect for the treatment of psoriasis.
- the present invention thus relates to a vesicle comprising:
- R 1 is chosen from H and a linear or branched, saturated or unsaturated, 1 to 20 membered hydrocarbon chain, in particular R 1 is chosen from H and C1-C20- alkyl, more particularly, R 1 is chosen from H and C4 -C18-alkyl, more particularly R 1 is H, and
- R 2 is a linear or branched, saturated or unsaturated, 1 to 20 membered hydrocarbon chain, in particular R 2 is C1-C20-alkyl, more particularly R 2 is C4-C18-alkyl, more particularly R 2 is C8- C16-alkyl, always more particularly R 2 is dodecyl,
- R 3 and R 4 are independently of each other a linear or branched, saturated or unsaturated, 1 to 19 membered hydrocarbon chain, in particular R 3 and R 4 are independently of one another C1-C19 -alkyl, more particularly R 3 and R 4 are C3-C17-alkyl, more particularly R 3 and R 4 are C7-C15-alkyl, always more particularly R 3 and R 4 are undecyl; and - a dendrimer of formula (II):
- R is chosen from H and C1 -C12-alkyl, in particular R is C1 -C12-alkyl, more particularly R is C1-C8-alkyl, more particularly R is C1-C4-alkyl, always more particularly R is chosen from methyl, n-hexyl and n-octyl;
- A is selected from and, where X is selected from S and O; in in particular A is, where X is selected from S and O; more particularly X is S, and n is an integer between 3 and 8, in particular n is equal to 6.
- alkyl is meant within the meaning of the present invention a hydrocarbon radical of formula C n H 2n + 1 in which n is an integer greater than or equal to 1.
- the alkyl radicals can be linear or branched, preferably linear.
- Particular alkyl radicals of the invention are from 1 to 20 carbon atoms, more particularly from 1 to 12 carbon atoms.
- sugar is meant within the meaning of the present invention monosaccharides, disaccharides, polysaccharides, polyols and their derivatives.
- Sugar derivatives include in particular sugar-type radicals in which a hydroxyl function has been deleted.
- a particularly preferred sugar of the invention is 1-deoxylactilol.
- the vesicle according to the invention is characterized in that it comprises a single catanionic surfactant of formula (I).
- the vesicle according to the invention is characterized in that it comprises a mixture of catanionic surfactants of formula (I), in particular a mixture of two different catanionic surfactants of formula (I).
- the molar ratio between the two different catanionic surfactants of formula (I) can be between 99/1 and 1/99.
- the vesicle according to the invention is characterized in that, in the catanionic surfactant of formula (I), is 1-deoxylactilol.
- the catanionic surfactant present in the formulation is that of formula (Ia):
- the vesicle according to the invention is characterized in that, in the dendrimer of formula (II), is
- the dendrimer present in the vesicle is that of formula (IIa):
- the dendrimer of formula (IIa) present in the vesicle is that in which Z is -CH 2 -. According to another variant of this embodiment, the dendrimer of formula (IIa) present in the vesicle is that in which A is where X is chosen from S and O.
- the dendrimer of formula (IIa) present in the vesicle is that in which A is
- the catanionic surfactant / dendrimer molar ratio in the vesicle according to the invention is between 50/1 and 1/1, in particular between 30/1 and 1/1, more particularly between 20/1 and 1 / 1, even more particularly between 10/1 and 1/1, always more particularly between 5/1 and 1/1.
- the catanionic surfactant / dendrimer molar ratio in the vesicle according to the invention is approximately 2/1.
- the vesicle according to the invention makes it possible to encapsulate the dendrimer in the catanionic surfactant.
- the degree of encapsulation of the dendrimer of formula (I) in the catanionic surfactant of formula (II) is greater than 50%.
- the degree of encapsulation of the dendrimer of formula (I) in the catanionic surfactant of formula (II) is between 50% and 95%, more particularly between 60% and 85%, more particularly still between 70% and 80%. %.
- the term “encapsulation rate” is understood to mean the ratio between the number of moles of dendrimer stabilized in the catanionic surfactant over the number of moles of dendrimer initially used for the preparation of the vesicle.
- the degree of encapsulation can be determined by all the methods known to those skilled in the art, in particular by assay by UV-visible spectrophotometry or by fluorescence spectroscopy.
- the average diameter of the vesicles according to the invention is between 50 and 500 nm, in particular between 100 and 350 nm.
- the average diameter can be determined by all the methods known to those skilled in the art, in particular by dynamic light scattering (DLS), in particular by means of a He-Ne laser emitting a monochromatic light of a wavelength of 633 nm.
- the phase transition temperature of the vesicles according to the invention is between 30 and 35 ° C, in particular is 33 ° C.
- the present application also relates to a process for preparing the vesicles as described above.
- the catanionic surfactant of formula (I) present in the vesicle according to the invention is formed by the combination of an N-alkylaminosugar of formula (G):
- R 1 is chosen from H and a linear or branched, saturated or unsaturated, 1 to 20 membered hydrocarbon chain, in particular R 1 is chosen from H and C1-C20-alkyl,
- R 2 is a linear or branched, saturated or unsaturated, 1 to 20 membered hydrocarbon chain, in particular R 2 is C1-C20-alkyl; and a phosphinic acid of formula (I ”):
- R 3 and R 4 are independently of each other a linear or branched, saturated or unsaturated, 1 to 19 membered hydrocarbon chain, in particular R 3 and R 4 are independently of one another C1-C19 -alkyl.
- the process for preparing a vesicle according to the invention successively comprises the following steps:
- the mixing step is carried out in an aqueous solution, in particular in water.
- the N-alkylaminosugar, the phosphinic acid and the dendrimer are mixed with a molar ratio of between 100/50/1 and 1/1/1.
- the mixing step is carried out with an N-alkylaminosugar / phosphinic acid / dendrimer molar ratio of 2/2/1.
- the mixing can be carried out by means of all the techniques known to those skilled in the art, in particular by magnetic stirring, by vortex stirring and / or by sonication by ultrasound, more particularly by vortex stirring and then by magnetic stirring or by ultrasound sonication.
- the mixing step can be carried out at room temperature or by heating at a temperature between room temperature and 100 ° C, in particular between 25 ° C and 75 ° C, for a period of between 5 minutes and 72 hours, especially between 10 minutes and 48 hours.
- the vesicle obtained can then be separated from the non-encapsulated dendrimer.
- the separation step can be carried out by means of all the techniques known to those skilled in the art, in particular by filtration.
- composition A subject of the present patent application is also a pharmaceutical composition comprising the vesicle as described above and a pharmaceutically acceptable excipient.
- a pharmaceutically acceptable excipient does not produce a side effect, allergic or other adverse reaction when administered to an animal, preferably a human.
- the preparations must meet the criteria of sterility, pyrogenicity, general safety and purity standards as required by regulatory agencies, such as for example the FDA or IMA.
- composition as described above will be intended for topical or transcutaneous application.
- the pharmaceutical composition as described above can thus comprise one or more pharmaceutically acceptable excipients for a formulation suitable for topical administration.
- compositions for topical application in the form of a milk, a cream, a balm, an oil, a lotion, a gel, a foaming gel, an ointment, or a spray, preferably in the form of a gel.
- the pharmaceutical excipients can be gelling agents chosen from: carbomers, polysaccharides, such as xanthan gum, guar gum, chitosans, carrageenans, cellulose and its derivatives such as hydroxypropylmethylcellulose in particular or hydroxyethylcellulose available under the name Natrosol or also the family of aluminum and magnesium silicates, the family of acrylic polymers, the family of modified starches and the gelling agents of the family of polyacrylamides.
- the pharmaceutical excipient comprises hydroxyethylcellulose, chitosan or xanthan, preferably xanthan. Therapeutic use
- the inventors have shown that the dendrimers according to the invention have, in addition to an anti-inflammatory effect, an anti-proliferative effect on the keratinocytes.
- the formulation of dendrimers in vesicles according to the invention allows the active principle to cross the stratum corneum and to reach the region of proliferation of keratinocytes in the deep epidermis.
- the present patent application relates to the vesicle or the pharmaceutical composition of the invention as described above for its use for the treatment or prevention of dermatosis linked to hyperproliferation of keratinocytes and / or to a context inflammatory, preferably psoriasis, dermatitis such as atopic dermatitis, contact dermatitis, seborrheic dermatitis or ichthyosis, such as erythematous ichthyosis (rare diseases) such as Peeling Skin Syndrom (PSS) type 1 or 6 or congenital ichthyosiform erythroderma, squamous cell carcinoma, basal or squamous cell carcinoma or acne.
- a context inflammatory preferably psoriasis, dermatitis such as atopic dermatitis, contact dermatitis, seborrheic dermatitis or ichthyosis, such as erythematous ichthyosis (rare diseases)
- the present patent application relates to the vesicle or the pharmaceutical composition of the invention as described above for its use for the treatment or prevention of dermatosis linked to hyperproliferation of keratinocytes and to a inflammatory context, preferably dermatitis such as atopic dermatitis, contact dermatitis, seborrheic dermatitis or ichthyosis, such as erythematous ichthyosis (rare diseases) such as Peeling Skin Syndrom (PSS) type 1 or 6 or Congenital ichthyosiform erythroderma. Dermatitis corresponds to irritation of the skin. Dermatitis is a common condition and comes in many forms.
- dermatitis such as atopic dermatitis, contact dermatitis, seborrheic dermatitis or ichthyosis, such as erythematous ichthyosis (rare diseases) such as Peeling Skin Syndrom (PSS) type 1 or 6 or Congenital ich
- the vesicle or the pharmaceutical composition of the invention as described above is particularly useful for treating atopic dermatitis, contact dermatitis and seborrheic dermatitis.
- Atopic dermatitis also called atopic eczema, is a chronic inflammatory disease of the skin. It develops preferentially in infants and children, but can persist or even appear sometimes in adolescents and adults. It is characterized by skin dryness associated with eczema-like lesions (redness and itching, blisters, oozing and scabs) which develop in flare-ups.
- Atopic dermatitis is a chronic inflammatory disease of the skin.
- Contact dermatitis designates a skin reaction resulting from exposure to allergenic (allergic contact dermatitis) or irritant (irritant dermatitis) substances.
- the skin reaction usually develops a few minutes to a few hours after exposure to the substance and can last for two to four weeks.
- Seborrheic dermatitis typically affects the scalp and causes scaly patches, red skin, and stubborn dandruff. It can also affect fatty areas of the body, such as the face, upper chest and back. Seborrheic dermatitis can be a long-lasting condition, with periods of improvement and then seasonal flare-ups. In infants, this condition is called "cradle cap”.
- the vesicle or the pharmaceutical composition of the invention as described above is particularly useful also for treating ichthyosis, preferably erythematous ichthyosis such as "Peeling Skin Syndrom (PSS))" type 1 or 6 or congenital ichthyosiform erythroderma.
- ichthyosis preferably erythematous ichthyosis such as "Peeling Skin Syndrom (PSS))" type 1 or 6 or congenital ichthyosiform erythroderma.
- Ichthyosis is a congenital disease of the skin which is characterized by extremely dry, rough skin, by the presence of an excessive amount of fine scales with a free edge, sometimes arranged like fish scales which are continuously detached.
- Erythematous ichthyosis is an ichthyosis presenting a dermatological lesion characterized by congestive redness of the skin, diffuse or localized, disappearing with vitopression.
- Type 1 or 6 skin syndrome peels are inflammatory forms of ichthyosis characterized by diffuse and superficial desquamation of the entire skin surface with underlying erythroderma, pruritus and atopy.
- Congenital ichthyosiform erythroderma is characterized by the presence from birth of fine grayish-white scales of different sizes, associated with erythroderma. Some newborns are wrapped in a soft collodion wrap (tight, shiny, and translucent) and develop scaly erythroderma after peeling.
- a subject of the present patent application is also the vesicle or the pharmaceutical composition as described above for its use for the treatment or prevention of dermatosis linked to hyperproliferation of keratinocytes, such as basal or spinoid carcinomas. - cellular.
- Basal cell carcinoma is a type of skin cancer that begins in the basal cells. Basal cell carcinoma often appears as a slightly transparent lump on the skin, although it can take other forms. Basal cell carcinoma most often appears on areas of the skin that are exposed to the sun, such as the head and neck.
- Squamous cell carcinoma is a common form of skin cancer which develops in the squamous cells which make up the middle and outer layers of the skin. Squamous cell carcinoma most commonly occurs on skin exposed to the sun, such as the scalp, the backs of the hands, ears, or lips.
- a subject of the present application is also the vesicle or the pharmaceutical composition of the invention as described above for its use for the treatment or prevention of dermatosis linked to an inflammatory context such as acne.
- Acne is a common and chronic dermatological disease of the pilosebaceous system (which comprises the hair follicle, the hair shaft and the sebaceous gland secreting sebum, at the root of the hair). It usually occurs in adolescence and is linked to hypersecretion of sebum (hyperseborrhea) and keratinization abnormalities leading to obstruction of the excretory duct of the pilosebaceous follicle, and the formation of comedones.
- the present patent application also relates to the vesicle or the pharmaceutical composition as described above for its use for the treatment of psoriasis in a subject who needs it.
- Psoriasis is a dermatosis linked to hyperproliferation of keratinocytes, cells constituting 90% of the epidermis, and to a chronic inflammatory context.
- keratinocytes play a role, alongside immune cells of the skin and infiltrating immune cells.
- the hyperproliferation of the keratinocytes is accompanied by a defect of differentiation when they reach the most superficial layer of the epidermis, the stratum corneum, hence the desquamation plaques characteristic of the disease.
- the different layers of the epidermis are renewed in 3 to 4 days, compared to 3 weeks for normal skin.
- the vesicle or the pharmaceutical composition according to the application is particularly useful for the treatment of psoriasis.
- psoriasis is meant a chronic inflammatory disease of the skin inducing abnormal renewal of the skin causing thick red patches covered with scales.
- psoriasis is meant all forms of psoriasis, including plaque psoriasis, guttate psoriasis, psoriasis in infants, pustular psoriasis, erythrodermic psoriasis, reverse psoriasis, psoriasis of the face, scalp, skin. mucous membrane nail.
- Plaque psoriasis or vulgar psoriasis, is the most common form affecting more than 80% of patients and is characterized by raised red patches with white scales on the surface.
- Guttate psoriasis which affects nearly 10% of patients, is characterized by lesions multiple teardrop-shaped with few scales.
- Pustular psoriasis is the most serious form of psoriasis in which the plaques are covered with white, non-infectious pustules.
- Erythrodermic psoriasis is a generalized inflammation with scales in which 90 to 100% of the skin is affected.
- Reverse psoriasis is characterized by the presence of non-scaly plaques inside the joints and folds.
- subject refers to an animal, more particularly a mammal.
- the subject is a human.
- a subject may be a patient, namely a person receiving medical care, undergoing or having undergone medical treatment, or being monitored for the development of a disease.
- treat refers both to a therapeutic treatment and to prophylactic or preventive measures, in which the objective is to prevent or slow down (decrease) the targeted pathological condition, in particular proliferation of keratinocytes and inflammation of the skin.
- the objective is to reduce the surface area of the affected skin, to reduce the degree of redness of the lesions, their thickness and the intensity of the scaling.
- the vesicle or the composition as described above for its use as a medicament in particular for the treatment or prevention of dermatosis linked to hyperproliferation of keratinocytes and / or to an inflammatory context, preferably for Psoriasis treatment are characterized in that they are formulated for topical application.
- the present invention relates to a method of treatment or prevention of a dermatosis linked to hyperproliferation of keratinocytes and / or to an inflammatory context in a subject who needs it, comprising the administration.
- a therapeutically effective dose of a vesicle or a pharmaceutical composition according to the invention to a subject, a therapeutically effective dose of a vesicle or a pharmaceutical composition according to the invention.
- the subject is an animal, preferably a mammal, more preferably a human suffering from a dermatosis linked to hyperproliferation of keratinocytes and / or to an inflammatory context.
- the present invention also relates to the use of a vesicle or a pharmaceutical composition as described above for the manufacture of a medicament for the treatment or prevention of dermatosis linked to hyperproliferation of keratinocytes and / or to an inflammatory context.
- the present patent application also relates to a method of treating psoriasis in a subject in need thereof comprising the administration of a therapeutically effective dose of the vesicle or of the composition as described above in said subject.
- the present application relates to a method of treating psoriasis in a subject in need thereof comprising the topical administration of a therapeutically effective dose of the vesicle or the pharmaceutical composition as described above in said subject.
- the present invention also relates to the use of a vesicle or a pharmaceutical composition as described above for the manufacture of a medicament for the treatment or prevention of psoriasis.
- terapéuticaally effective dose refers to the dose of therapeutic agent necessary and sufficient to slow down or stop the progression, worsening or deterioration of one or more symptoms of a dermatosis linked to hyperproliferation.
- keratinocytes and / or an inflammatory context as described above preferably psoriasis disease, for example reducing the area of the affected skin, reducing the degree of redness of the lesions, their thickness and the intensity of the scaling.
- the vesicle or a pharmaceutical composition as described above can be used as a medicament in particular for the treatment or prevention of dermatosis linked to hyperproliferation of keratinocytes and / or to an inflammatory context such as as described above, preferably psoriasis in a subject in combination with at least one other therapeutic agent.
- additional therapeutic agents include, but are not limited to anti-inflammatory agents, anti-infective agents or immunosuppressive agents.
- the gallbladder and the additional therapeutic agent can be administered by at the same time or at different times, simultaneously or separately.
- the treatment methods and pharmaceutical compositions of the present invention can use the vesicle of the invention in the form of monotherapy, but these methods and compositions can also be used in the form of combination therapy in which the vesicles of the invention are co-administered in combination with one or more other therapeutic agents
- the reactor After three purges at 20 bars of hydrogen, the reactor is filled with hydrogen at 22 bars then separated from the hydrogen bottle and placed in a sand bath thermostated at 60 ° C, so as to have a temperature of about 50 ° C in the reactor.
- the reaction medium is thus left under magnetic stirring for 3 days.
- the reaction medium is returned to atmospheric pressure.
- filtration of the reaction medium is carried out on Celite using a filter of porosity 5.
- the reaction medium heated to 50 ° C. is deposited, then washed with 200 ml_ of ultrapure water / methanol solution (1: 1) at 50 ° C.
- the filtrate is then dried in a rotary evaporator. When only water remains, it is removed by lyophilization.
- the latter is washed successively with 15mL of ultrapure water, 15mL of tetrahydrofuran (THF), 4x15mL of acetone, 15mL of ultrapure water, 15mL of tetrahydrofuran, 4x15mL of acetone and 15mL of tetrahydrofuran.
- the washes are all carried out using a frit of porosity 4.
- the ABP dendrimer was synthesized according to the protocol described in Poupot et al. FASEB J. 2006, 20 (13) 2339-51.
- the G1-A dendrimer was synthesized according to the protocol described in Poupot et al. FASEB J. 2006, 20 (13) 2339-51.
- reaction medium is lyophilized, the crude residue is dissolved in 50 mL of dichloromethane (DCM) then washed with water (3 x 25 mL). The organic phase is dried and concentrated under reduced pressure. The residue is purified on a silica column (eluent: hexane / AcOEt, 60/40) to give product b with a yield of 85% in the form of a transparent oil.
- DCM dichloromethane
- the G1-B dendrimer is synthesized according to the reaction scheme presented in scheme 3:
- the compound 1-G "' 0 -HCl (300 mg) is dissolved in 25 ml of distilled water to which is added 25 ml of a solution of NaOH (2M). The aqueous phase is then extracted 3 times with 200 mL of CH 2 Cl 2. The organic phase is then dried with Na 2 SO 4, filtered and concentrated under vacuum to give the dendrimer 1-G "' 0 in the form of a transparent oil with a yield of 80%.
- the compound G1-B is not sufficiently soluble in water to be analyzed by NMR, it is converted into sodium mono salt according to the following procedure:
- the compound is then converted into a sodium salt for analysis.
- To a suspension of the phosphonic acid compound in water with stirring are added 24 equivalents of an aqueous solution of 0.1 M NaOH.
- the resulting solution is filtered through a 0.4 ⁇ M microfilter and then lyophilized to give the expected compound in the form of a white powder with a yield of 90%.
- the formulation of the dendrimer is obtained by mixing in water the catanionic surfactant TriCat-n and the dendrimeric acid precursor G1-X [Fig. 1],
- TriCat8 The formula of TriCat8 is as follows: [0277] [Chem 43]
- ABP dendrimer To 5.82 mg of ABP dendrimer, 1.02 mg of N-dodecylamino-1-deoxylactitol (L-Hyd 12) and 0.87 mg of bis-a- (hydroxydodecyl) phosphinic acid are added at temperature ambient 2 ml of ultrapure water. The mixture is vortexed for 5 min then sonicated using an ultrasonic probe for 15 min at power 3 with 30% of active cycles while controlling the temperature at 45 ° C.
- L-Hyd 12 N-dodecylamino-1-deoxylactitol
- bis-a- (hydroxydodecyl) phosphinic acid To 5.82 mg of ABP dendrimer, 1.02 mg of N-dodecylamino-1-deoxylactitol (L-Hyd 12) and 0.87 mg of bis-a- (hydroxydodecyl) phosphinic acid are added at temperature ambient 2 ml
- a 5.21 mg of G1-B dendrimer, 1.16 mg of N-hexadecylamino-1-deoxylactitol (L-Hyd 16) and 0.86 mg of bis-a- (hydroxydodecyl) phosphinic acid are added at room temperature 2 mL of ultrapure water. The mixture is vortexed for 5 min then left under magnetic stirring (500 rpm) at 40 ° C. for 15 minutes then for 24 h at room temperature.
- the size and size distribution of the vesicles is measured by DLS (dynamic light scattering). Each analysis is carried out on the samples, filtered at 1.2 ⁇ m with a Minisart cellulose acetate filter, placed in plastic tanks (semi-micro polystyrene tanks, Brand). The measurements are carried out on a Malvern Instruments Nano S or Nano ZS device, both equipped with a He-Ne laser that emits a light monochromatic wavelength 633 nm. The scattered intensity is measured at 25.0 ° C ⁇ 0.1 ° C at an angle of 173 °. The result is an average of 4 measurements and was processed by the Contin algorithm.
- DLS dynamic light scattering
- the samples are prepared saturated at 1 .10 -2 M in TriCat12. Equimolar amounts of L-Hyd12 and phosphonic acid are dispersed at a concentration of 1 .10 -2 M and of dendrimer at a concentration of 5.10 -4 M in 2 ml of water. The mixture is stirred at 300 rpm for 2 days. Two methods are carried out: the first consists in lyophilizing the medium and then dispersing it in 100 ⁇ L of water followed by the conventional vesicle formation protocol. The second method consists in immediately sonicating 100 ⁇ L of the medium without going through the freeze-drying step. An identical result is obtained by both methods.
- Another method consists in immediately sonicating the mixture following the conventional protocol without going through the stirring step, similar results are obtained but with this method there is more background noise.
- the measurements are then carried out on a DSC 1 STARe System device with MultiSTAR® HSS8 sensor.
- the sample crucible and the reference crucible are placed in the same furnace.
- the reference is filled with 75 ⁇ L of the solvent while 75 ⁇ L of the solution to be analyzed is placed in the sample crucible.
- the method developed consists in bringing the sample from 25 to 5 ° C at 5 ° C / min then to make 4 cycles of 5 to 60 ° C at 2 ° C / min.
- the total amount of G1-X-NIR was determined by measuring the fluorescence intensity (IF) of a sample for which the vesicular structures were broken by adding methanol to the solution. (1mL of methanol for 20 ⁇ L of vesicular solution).
- IF fluorescence intensity
- the vesicles were observed by scanning electron microscopy after freeze-fracture (cryoMEB).
- the apparatus used for the analysis is an ESEM Quanta FEG250 from the company FEI (TRI-Genotoul platform), operating at 5 kV and approximately 1.10 '4 Pa.
- the solutions are deposited on the sample holder and then solidified in pasty nitrogen (-210 ° C). They are then fractured in a chamber at -140 ° C.
- the sample then undergoes a sublimation step at -90 ° C. for 5 minutes.
- the sample then undergoes a 60 s platinum metallization by plasma. It is transferred for observation in the cryogenic chamber of the SEM, maintained at all times at -140 ° C by a flow of nitrogen gas.
- TriCat12 / dendrimer solutions are stored at 4 ° C. in DLS tanks. When the size is measured, the solution is placed at room temperature for 5 min then the size is measured at 25 ° C. in DLS.
- a 2% wt xanthan solution in water is prepared: 20 mg of xanthan are added in rain with stirring at 500 rpm in 1 mL of mQ water filtered at 0.2 ⁇ m. The mixture is stirred for 1 hour minimum. Then, an equivolume mixture of Tricat12 / G1-X vesicles and 2% wt xanthan gel is produced. The mixture is left stirring at 500rpm for a minimum of 4 hours.
- the resulting powder is moistened with a few drops of D20 before analysis by solid NMR (MAS NMR). 12. Evaluation of skin penetration in vitro on Franz cell
- the Franz type continuous flow cell diffusion method (PermGear®, Standard Franz Cells) is used to study in vitro the cutaneous penetration of the formulation over time without disturbing the system. These experiments were performed on the skin of pig ears which represents a predictive model of human skin penetration, having histological and physiological properties similar to human skin. Samples of pig ear skin were obtained from the slaughterhouse (Arcadie Sud-rium, Montauban), so that the skin tissue was intact. After dissection of the skin from the underlying tissue, the skin is cleaned with water, degreased, depilated and then cut into square pieces of about 2 cm. These skin patches are frozen at -80 ° C for subsequent use.
- the skins were thawed at room temperature and placed on the Franz cells in the donor compartment so that the face bathed in the receiving liquid corresponds to the internal face of the skin while the face which is in contact with air is that of the stratum corneum.
- a fluorescent dendrimer analog is used with near infrared emission (G1-X-NIR), for skin penetration and retention studies in vitro.
- a dose 300 ⁇ l) of PBS (white), G1-X-NIR alone or formulated in TriCat12 / G1-X-NIR vesicles was deposited on the face of the stratum corneum, using a micropipette, to cover the area. diffusion surface of 1.77 cm 2 for 24 h. The outer surface of the cell was covered with parafilm to prevent evaporation and changes in volume.
- PBS phosphate buffer solution
- the skin is rinsed with PBS in order to remove the rest of the deposit and dried with absorbent paper.
- the treatment area is then cut into small pieces in a pill container with 3 mL of PBS and homogenized using a disperser (Ultra-Turrax Ika®- Werke, T 25 Basic) for 5 min at 21,500 rpm.
- Confocal microscopy is chosen to assess the depth of penetration of G1-X-NIR into the different layers of the skin (stratum corneum, viable epidermis and the dermis).
- the first step is the diffusion of G1 - X-NIR on Franz cell, according to the protocol described above.
- the skin is gently rinsed with PBS and dried.
- PBMCs peripheral blood mononuclear cells
- PANBiotech GmbFI Pancoll's solution
- monocytes are isolated by negative selection with antibodies directed against all blood cells (T cells, B cells, NK cells, dendritic cells, erythrocytes and granulocytes) except monocytes using the Dynabeads® Untouched kit TM Fluman Monocytes (Invitrogen). The purity of the monocytes was verified, by flow cytometry, greater than 90% for each donor with anti-CD14-APC-Cy7 antibody (Miltenyi Biotec).
- the freshly purified monocytes were resuspended in a 48-well plate at 1 million per ml in RPMI 1640 + GLUTAMAX, penicillin and streptomycin at 100 U / ml and 10% fetal calf serum (FCS). All the molecules were added at the start of the cultures at a concentration of 20 ⁇ M of G1-X except the TriCat12 alone at a concentration of 40 ⁇ M.
- FCS fetal calf serum
- mice 8-week-old Balb / c female mice, weighing approximately 20 g, were used during these experiments.
- the experimental procedures have been evaluated and approved by the Ethics Committee in Animal Experimentation.
- the gestures and experimental procedures are performed under gas anesthesia, performed in an anesthesia station by inhalation of 4% isoflurane in the induction box and then 3% with a mask. After a week of acclimatization, the backs of the mice are shaved on D-1, over an area of about 4 cm 2 using a trimmer, and the residual hairs are removed using a cream depilatory.
- mice On D7, 5 hours after the last treatment, the mice are euthanized.
- the severity of the inflammation of the skin of the back of the mice was assessed using a clinical score based on the Psoriasis Area Severity Index (PASI) score.
- PASI Psoriasis Area Severity Index
- Back thickness was measured using a caliper.
- a total clinical score combining these three clinical criteria was then calculated (scale from 0 to 12).
- HE staining is carried out on 5 ⁇ m sections of dewaxed skin. The images are obtained using a slide scanner (Panoramic slide scanner 250, 40x objective). The severity of the inflammation, histologically, was assessed based on the following histopathologic features of psoriasis: acanthosis, spongiosis, hyperkeratosis, parakeratosis and immune infiltrate. For each of these five criteria, a score ranging from 0 (normal) to 4 (severe) was assigned, then the scores were cumulated to give the total histological score (scale from 0 to 20).
- the expression of the proliferation marker Ki67 was studied by immunohistochemistry after treatment or not (control) with 20 ⁇ M of G1-A or of G1-B for 24, 48 or 72 hours.
- Two types of keratinocytes were studied: the human line N-TERT and primary human keratinocytes. Following treatment with the dendrimers, the cells are washed, fixed in para-formaldehyde (PFA) and permeabilized with triton.
- PFA para-formaldehyde
- the fixed cells are incubated with a rabbit primary antibody directed against Ki67, then washed and incubated with an anti-rabbit secondary antibody coupled to the Alexa Fluor 488 fluorochrome.
- the nuclei of the cells are labeled with 4 ', 6-diamidino- 2-phenylindole (DAPI).
- DAPI 6-diamidino- 2-phenylindole
- the keratinocytes were then observed with a wide-field fluorescence microscope. For each observation zone, two images are acquired: one with the ultraviolet laser to observe the marking of the nuclei with DAPI; one with the green laser to observe the marking of Ki67. These images are processed with ImageJ software. On the image corresponding to the DAPI marking, the nuclei are counted in order to obtain the total number of cells per image. On the image corresponding to labeling of Ki67, the nuclei positive for Ki67 are counted in order to obtain the number of cells which are proliferating, and to calculate the percentage of prolife
- the process for preparing the TriCat12 / ABP formulation makes it possible to obtain vesicles whose average diameter is around 250-300 nm with a bilayer transition temperature of 37 ° C [Fig. 2],
- the process for preparing the TriCat12 / ABP formulation is capable of encapsulating on average between 25% of the dendrimer initially used in the formulation.
- the separation of the non-encapsulated dendrimer is difficult to access with the techniques known to those skilled in the art.
- the Zeta potential is -55 ⁇ 4 mV and the pH of the solution ⁇ 6.5.
- the process for preparing the formulation involving a precursor, the dendrimer in its phosphonic acid form makes it possible to increase its capacity for insertion into the hydrophobic part of the vesicles and thus to obtain an average degree of encapsulation of 75 % and simply separate the non-encapsulated active by filtration.
- the formulation of the G1-A dendrimer by TriCat-12 gives rise to the formation of vesicles, the average diameter of which is around 100-350 nm [Fig. 4].
- the TriCat 12 / G1-A formulation has a phase transition temperature of 33 ° C. Below 33 ° C, the membrane bilayer of the vesicle is rigid and stable. Above 33 ° C (the skin temperature oscillating between 30 and 35 ° C), this membrane becomes fluid and its bio-addressing properties are increased (diffusion in the tissues, fusion with the cells, release of the active ingredients) [Fig. 5].
- the Zeta potential is -53 ⁇ 2.5 mV and the pH of the solution ⁇ 2.8.
- the formulation of the G1-A-NIR dendrimer by TriCat-12 gives rise to the formation of vesicles, the mean diameter of which is around 100-350 nm.
- the pH of the solution is ⁇ 2.8.
- the TriCat 12 / G1-A-NIR formulation is stable for at least 1 month when stored at 4 ° C in solution.
- the TriCat 12 / G1-A formulation is stable for more than two months when stored at 4 ° C in solution [Fig. 6].
- the Franz type continuous flow cell diffusion method is used to study in vitro the cutaneous penetration of the formulation over time. These experiments were carried out on pig ear skins, which have histological and physiological properties similar to those of human skin. These experiments show that after 24 hours, the amount of dendrimer which has penetrated the skin is significantly greater when it is formulated [Fig. 8]).
- a change in morphology (increase in granulosity and size) reflects activation of primary human monocytes.
- the results show that the TriCat12 vesicles alone do not modify the morphology of human monocytes, while the TriCat12 vesicles loaded with the G1-A dendrimer cause an increase in granulosity and size.
- nearly half of the cells are in the ellipse of activated monocytes [Fig. 11],
- mice control: untreated IMQ mice, IMQ mice treated with 13 mg / kg of free G1-A dendrimer, and mice treated with 13 mg / kg of G1 dendrimer -A formulated in TriCat12 vesicles
- mice show a decrease in the clinical score in the 2 treated groups.
- the mean clinical score is 9.5 on D7.
- the clinical score was reduced to 6.5 and 5.7 for the free G1-A dendrimer and TriCat12 / G1-A formulated dendrimer groups, respectively [Fig. 12, top graph],
- the mean histological score is also reduced from 16.5 for the untreated control mice to 14.5 and 10.4 for the free G1-A dendrimer and TriCat12 / G1-A dendrimer groups, respectively [Fig. 12, bottom graph].
- FIG. 13 shows the antiproliferative effect of compound G1-A, as a function of the treatment time, on the N-TERT keratinocyte line (top graphs) and on primary human keratinocytes (bottom graphs). A decrease in total cell number and percentage of proliferative cells is observed [Fig. 13].
- the Zeta Potential is -41 ⁇ 2.6 mV and the pH of the solution ⁇ 2.7
- the membrane bilayer of the formulations is rigid and very stable. Above 33 ° C (the temperature of the skin oscillating between 30 and 35 ° C), this membrane becomes fluid and its bio-addressing properties are increased (diffusion in the tissues, fusion with the cells, release of the active ingredients ) [Fig. 15].
- the formulations are stable (in terms of diameter and quantity (represented by the diffused intensity DCR)) for more than two months when they are stored at 4 ° C. in solution [Fig. 16].
- TriCat 12 / G1-B vesicles in a xanthan gel For the formulation of the TriCat 12 / G1-B vesicles in a xanthan gel, no significant modification of the transmission through the sample is observed over the entire height of the sample after 24 h, whereas for the TriCat vesicles 12 / G1-B stored in water transmission increases at the top of the volume showing clarification of the solution due to slight sedimentation of the vesicles.
- the pharmaceutical formulation of the vesicles in the xanthan gel thus allows better storage at room temperature.
- the Franz type continuous flow cell diffusion method is used to study the in vitro skin penetration of the formulation over time. These experiments were carried out on pig ear skins, which have histological and physiological properties similar to those of human skin. These experiments show that after 24 h, the amount of G1-B-NIR dendrimer which has penetrated the skin is significantly greater when it is formulated in the TriCat 12 / G1-B-NIR vesicles [Fig. 19]).
- a change in morphology (increase in granulosity and size) reflects activation of primary human monocytes.
- the results show that TriCat12 vesicles alone do not modify the morphology of human monocytes [Fig. 11], whereas the TriCat12 vesicles loaded with the G1-B dendrimer cause an increase in granulosity and size.
- nearly 2/3 of the cells are in the ellipse of activated monocytes [Fig. 22],
- the mean histological score is also reduced from 14.8 for the untreated control mice to 12.4 and 10.8 for the free G1-B dendrimer and TriCat12 / G1-B dendrimer groups, respectively [Fig. 23, bottom graph].
- FIG. 24 shows the antiproliferative effect of compound G1-B, as a function of the treatment time, on the N-TERT keratinocyte line (top graphs) and on primary human keratinocytes (bottom graphs). A decrease in the total number of cells and the percentage of proliferative cells is observed.
- the membrane bilayer of the formulations is rigid and very stable. Above 34 ° C (the temperature of the skin oscillating between 30 and 35 ° C), this membrane becomes fluid and its bio-addressing properties are increased (diffusion in the tissues, fusion with the cells, release of the active ingredients ) [Fig. 26].
- the formulations are stable (in terms of diameter) for more than a month when they are stored at 4 ° C. in solution [Fig. 27],
- a change in morphology (increase in granulosity and size) reflects activation of primary human monocytes.
- the results show that the G1-C dendrimer at 20 ⁇ M causes an increase in granulosity and in size. Furthermore, we note that nearly half of the cells are in the ellipse of activated monocytes [Fig. 29]
- TriCat-16 / G1 B formulations are stable (in terms of diameter) for more than 10 days when they are stored at 4 ° C in solution [Fig. 32],
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20851221.0A EP4081191A1 (fr) | 2019-12-23 | 2020-12-22 | Formulation d'un dendrimère anti-inflammatoire pour le traitement de psoriasis |
AU2020412366A AU2020412366A1 (en) | 2019-12-23 | 2020-12-22 | Anti-inflammatory dendrimer formulation for the treatment of psoriasis |
CA3165406A CA3165406A1 (fr) | 2019-12-23 | 2020-12-22 | Formulation d'un dendrimere anti-inflammatoire pour le traitement de psoriasis |
US17/787,787 US20230085651A1 (en) | 2019-12-23 | 2020-12-22 | Anti-inflammatory dendrimer formulation for the treatment of psoriasis |
IL294186A IL294186A (en) | 2019-12-23 | 2020-12-22 | Preparations containing dendrimers with anti-inflammatory activity for the treatment of psoriasis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1915517 | 2019-12-23 | ||
FR1915517A FR3104946B1 (fr) | 2019-12-23 | 2019-12-23 | Formulation d’un dendrimère anti-inflammatoire pour le traitement de psoriasis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021130453A1 true WO2021130453A1 (fr) | 2021-07-01 |
Family
ID=69903584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2020/052608 WO2021130453A1 (fr) | 2019-12-23 | 2020-12-22 | Formulation d'un dendrimère anti-inflammatoire pour le traitement de psoriasis |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230085651A1 (fr) |
EP (1) | EP4081191A1 (fr) |
AU (1) | AU2020412366A1 (fr) |
CA (1) | CA3165406A1 (fr) |
FR (1) | FR3104946B1 (fr) |
IL (1) | IL294186A (fr) |
WO (1) | WO2021130453A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005052031A1 (fr) | 2003-11-24 | 2005-06-09 | Rhodia Uk Ltd | Nouveaux dendrimeres a terminaisons bisphosphoniques et derives, leur procede de preparation et leur utilisation |
WO2010013086A1 (fr) | 2008-08-01 | 2010-02-04 | Centre National De La Recherche Scientifique | Dendrimères phosphorylés en tant que médicaments anti-inflammatoires |
-
2019
- 2019-12-23 FR FR1915517A patent/FR3104946B1/fr active Active
-
2020
- 2020-12-22 WO PCT/FR2020/052608 patent/WO2021130453A1/fr unknown
- 2020-12-22 CA CA3165406A patent/CA3165406A1/fr active Pending
- 2020-12-22 EP EP20851221.0A patent/EP4081191A1/fr active Pending
- 2020-12-22 US US17/787,787 patent/US20230085651A1/en active Pending
- 2020-12-22 AU AU2020412366A patent/AU2020412366A1/en active Pending
- 2020-12-22 IL IL294186A patent/IL294186A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005052031A1 (fr) | 2003-11-24 | 2005-06-09 | Rhodia Uk Ltd | Nouveaux dendrimeres a terminaisons bisphosphoniques et derives, leur procede de preparation et leur utilisation |
WO2010013086A1 (fr) | 2008-08-01 | 2010-02-04 | Centre National De La Recherche Scientifique | Dendrimères phosphorylés en tant que médicaments anti-inflammatoires |
EP2341915A1 (fr) * | 2008-08-01 | 2011-07-13 | Centre National de la Recherche Scientifique | Dendrimères phosphorylés en tant que médicaments anti-inflammatoires |
Non-Patent Citations (17)
Title |
---|
ANNE-MARIE CAMINADE ET AL: "The key role of the scaffold on the efficiency of dendrimer nanodrugs", NATURE COMMUNICATIONS, vol. 6, no. 1, 14 July 2015 (2015-07-14), XP055643363, DOI: 10.1038/ncomms8722 * |
BLANZAT MURIEL ET AL: "Dendritic catanionic assemblies: in vitro anti-HIV activity of phosphorus-containing dendrimers bearing galbeta1cer analogues", CHEMBIOCHEM,, vol. 6, no. 12, 1 December 2005 (2005-12-01), pages 2207 - 2213, XP002549180, ISSN: 1439-4227, [retrieved on 20051130], DOI: 10.1002/CBIC.200500203 * |
BRUN, A.ETEMAD-MOGHADAM, G.: "New double-chain and aromatic (alpha-hydroxyalkyl)phosphorus amphiphiles", SYNTHESIS, vol. 10, 2002, pages 1385 - 1390 |
F. IELASI ET AL: "Influence of PPH dendrimers' surface functions on the activation of human monocytes: a study of their interactions with pure lipid model systems", PHYSICAL CHEMISTRY CHEMICAL PHYSICS, vol. 18, no. 31, 1 January 2016 (2016-01-01), pages 21871 - 21880, XP055677714, ISSN: 1463-9076, DOI: 10.1039/C6CP03536A * |
FRUCHON ET AL., MOLECULES, vol. 18, no. 8, 2013, pages 9305 - 16 |
FRUCHON SÉVERINE ET AL: "Biodistribution and Biosafety of a Poly(Phosphorhydrazone) Dendrimer, an Anti-Inflammatory Drug-Candidate", BIOMOLECULES, vol. 9, no. 9, 11 September 2019 (2019-09-11), CH, pages 475, XP055791921, ISSN: 2218-273X, DOI: 10.3390/biom9090475 * |
FU H. ET AL., MOLECULES, vol. 16, 2014, pages 17715 - 17726 |
HAYDER M. ET AL., SCI TRANS MED, vol. 3, no. 81, 2011 |
HAYDER M., BIOMACROMOLECULES, vol. 16, 2015, pages 3425 - 3433 |
MYRIAM HAYDER ET AL: "Three-Dimensional Directionality Is a Pivotal Structural Feature for the Bioactivity of Azabisphosphonate-Capped Poly(PhosphorHydrazone) Nanodrug Dendrimers", BIOMACROMOLECULES, vol. 19, no. 3, 14 February 2018 (2018-02-14), pages 712 - 720, XP055719698, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.7b01398 * |
PORTEVIN D. ET AL., J TRANSI MED, vol. 7, 2009, pages 82 |
POUPOT ET AL., FASEB J., vol. 20, no. 13, 2006, pages 2339 - 51 |
ROLLAND ET AL., A EUROPEAN JOURNAL, vol. 14, 2008, pages 4836 - 4850 |
ROLLAND OLIVIER ET AL: "Tailored control and optimisation of the number of phosphonic acid termini on phosphorus-containing dendrimers for the ex-vivo activation of human monocytes", CHEMISTRY - A EUROPEAN JOURNAL, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 14, no. 16, 1 January 2008 (2008-01-01), pages 4836 - 4850, XP009116043, ISSN: 0947-6539, DOI: 10.1002/CHEM.200701063 * |
ROLLAND, O. ET AL., CHEMISTRY - A EUROPEAN JOURNAL, vol. 14, 2008, pages 4836 - 4850 |
S. A. KLYMCHENKOV. G. PIVOVARENKOO. TURAND. P. ALEXANDER, NEW JOURNAL OF CHEMISTRY, vol. 27, no. 9, 2003, pages 1336 - 1343 |
SABRINA CONSOLA ET AL: "Design of Original Bioactive Formulations Based on Sugar-Surfactant/Non-steroidal Anti-inflammatory Catanionic Self-Assemblies: A New Way of Dermal Drug Delivery", CHEMISTRY - A EUROPEAN JOURNAL, vol. 13, no. 11, 23 March 2007 (2007-03-23), DE, pages 3039 - 3047, XP055637570, ISSN: 0947-6539, DOI: 10.1002/chem.200601449 * |
Also Published As
Publication number | Publication date |
---|---|
EP4081191A1 (fr) | 2022-11-02 |
FR3104946B1 (fr) | 2022-08-12 |
CA3165406A1 (fr) | 2021-07-01 |
AU2020412366A1 (en) | 2022-07-14 |
US20230085651A1 (en) | 2023-03-23 |
IL294186A (en) | 2022-08-01 |
FR3104946A1 (fr) | 2021-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0275224A2 (fr) | Complexes phospholipidiques d'extraits de Vitis vinifera, leur procédé de préparation et compositions pharmaceutiques et cosmétiques les contenant | |
FR2597367A1 (fr) | Procede pour faciliter la formation de spherules lipidiques en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes. | |
EP2066408B1 (fr) | Composition a base de xanthoxyline et son utilisation en cosmetique | |
US20240033241A1 (en) | Composition for external use on skin for inflammatory diseases | |
FR2924430A1 (fr) | Procede de preparation de nanoparticules a base de molecules ou macromolecules amphiphiles fonctionnelles et leur utilisation | |
EP0318369B2 (fr) | Composition à base de phases lamellaires lipidiques hydratées ou de liposomes contenant de la tyrosine ou un dérivé de tyrosine et composition cosmétique ou pharmaceutique, notamment dermatologique, à activité pigmentante, l'incorporant | |
EP3197460B1 (fr) | Utilisation dermocosmetique ou pharmaceutique d'une composition contenant au moins un inhibiteur de certaines chimiokines | |
EP2662382B1 (fr) | Dérivés de stérol, leur procédé de préparation, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement du glioblastome multiple | |
CA2325887A1 (fr) | Procede d'obtention d'une huile enrichie en acides gras hydroxyoctadecadienoiques (hode) ou de ses esters, a partir d'un melange huileux contenant de l'acide linoleique, ou ses esters | |
WO2021130453A1 (fr) | Formulation d'un dendrimère anti-inflammatoire pour le traitement de psoriasis | |
EP0428440A1 (fr) | Nouveaux dérivés solubles et non toxiques des macrolides polyéniques basiques, leur préparation et leurs applications | |
WO1997002828A1 (fr) | Nouvelles compositions a base de phosphoglycero-ethers et leur utilisation dans le traitement des maladies neuro-degeneratives | |
WO1996020000A1 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique et milieu de culture, contenant un extrait de smelophyllum capense | |
EP2440551B1 (fr) | Mono esters et bis esters d'acide gras insature sur l'acide ascorbique et leurs utilisations cosmetiques | |
EP0699428B1 (fr) | Composition cosmétique ou dermatologique contenant des extraits de farine de mais encapsulés | |
CA3060365A1 (fr) | Derives amides des acides polycafeoylquiniques, procede de preparation et utilisations | |
WO2016135430A1 (fr) | Particules d'acide hyaluronique pour des applications cosmétiques ou dermatologiques | |
EP2825531B1 (fr) | Conjugués de vitamine c | |
WO2003000208A1 (fr) | Composition a usage topique comprenant un produit cytotoxique | |
EP4337222A1 (fr) | Prodrogue nucléolipidique antioxydante, composition pharmaceutique pour son administration et leurs utilisations thérapeutiques | |
KR20230145712A (ko) | 히알루론산 코팅된 프러시안 블루 나노입자 및 용도 | |
EP2714705B1 (fr) | Sucroses octasulfates de magnesium, leur preparation et leurs applications pharmaceutiques et cosmetiques | |
EP0396442A1 (fr) | Composition cosmétique contenant des composés obtenus par culture de cellules, notamment de fibroblastes ou de kératinocytes | |
FR2843696A1 (fr) | UTILISATION DE L'ENANTIOMERE S(+) DE L'ACIDE 2-HYDROXY-4-[3- HYDROXY-3-(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTYL) -1-PROPYNYL]BENZOïQUE DANS UNE COMPOSITION DERMATOLOGIQUE | |
CA2435561A1 (fr) | Medicament contre la differenciation des fibroblastes en adipocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20851221 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3165406 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020412366 Country of ref document: AU Date of ref document: 20201222 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020851221 Country of ref document: EP Effective date: 20220725 |